Clinical Trial Update: Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

View source ↗

Summary

A completed clinical trial assessing outcomes for metastatic renal cell carcinoma patients who received sunitinib after first-line immune-oncology treatments; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Renal Cell Carcinoma (mRCC) | Status: COMPLETED | Results posted: 2021-04-02